Two drugs have been approved in recent years in Europe for hospital-acquired and/or ventilator-associated bacterial pneumonia (HABP/VABP), but not in the U.S. At least 11 compounds are in clinical development to treat bacterial pneumonia. The three Phase I programs have the potential to go directly to Phase III based on data in other indications. Trius Pharmaceuticals Inc. (NASDAQ:TSRX) has tedizolid phosphate in Phase III for acute bacterial skin and skin structure infections (ABSSI). Cubist Pharmaceuticals Inc. (NASDAQ:CBST